5 citations
,
October 2018 in “Dermatologic therapy” Recognizing congenital triangular alopecia is crucial to avoid unnecessary treatments.
August 2019 in “Key engineering materials” A microemulsion with Carthamus tinctorius extract effectively inhibits 5α-reductase and improves skin and hair follicle delivery.
June 2021 in “Research Square (Research Square)” Adverse events in lung cancer treatments increase fear, anxiety, and depression, with newer therapies causing fewer side effects.
December 2018 in “International journal of women’s dermatology” FFA in young women is often missed, and no single treatment works best.
4 citations
,
April 2019 in “DOAJ (DOAJ: Directory of Open Access Journals)” 5-α-reductase inhibitors, intralesional steroids, and hydroxychloroquine are the most effective treatments for frontal fibrosing alopecia.
Trichoriboside treatment helps maintain scalp hair by increasing cAMP levels in hair follicles of men with hair loss.
May 2017 in “Journal of The American Academy of Dermatology” An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.
July 2020 in “DOAJ (DOAJ: Directory of Open Access Journals)” Excessive sun protection might contribute to frontal fibrosing alopecia.
August 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.
2 citations
,
August 2002 in “British Journal of Ophthalmology” Tangent screens help detect visual field defects from vigabatrin.
July 1989 in “British Journal of Dermatology” Long-term use of canthaxanthin may cause reversible changes in the eye, including crystal deposits and altered vision responses.
April 2023 in “World Journal Of Advanced Research and Reviews” Cosmetic products or emotional factors might contribute to Frontal Fibrosing Alopecia, and trichoscopy is useful for diagnosis.
December 2025 in “Actas Dermo-Sifiliográficas” Use a combination of oral dutasteride, topical treatments, and hydroxychloroquine to manage frontal fibrosing alopecia.
March 2026 in “British Journal of Dermatology” Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
July 2018 in “DOAJ (DOAJ: Directory of Open Access Journals)” The new gel formula could improve the delivery of a hair loss treatment through the skin and might be an alternative to taking it by mouth.
The authors suggest that 5-α-reductase inhibitors, like dutasteride, are effective in treating frontal fibrosing alopecia and should be the first-line treatment, with other options for severe cases. They also recommend further research on Janus kinase inhibitors.
32 citations
,
August 2016 in “Journal of the American Academy of Dermatology” Temporal triangular alopecia is a non-scarring hair loss in children, often linked to other health conditions.
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
March 2005 in “Journal of the American Academy of Dermatology” Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.
1 citations
,
January 2022 in “European Journal of Pharmacology” Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.
21 citations
,
March 2015 in “Journal of The American Academy of Dermatology” Vemurafenib therapy can cause hair loss, but clobetasol propionate foam can help regrow hair.
36 citations
,
October 2019 in “Cell Proliferation” Tryptanthrin effectively suppresses non-melanoma skin cancer and is safe for normal skin.
July 2025 in “Materials Today Bio” TFC-loaded microneedles effectively promote hair regrowth in androgenetic alopecia.
September 2022 in “Journal of the American Academy of Dermatology” The registry showed that tofacitinib is promising for treating hair loss in children with alopecia areata, but more research is needed.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
October 2022 in “Journal of Armed Forces Medical College, Bangladesh” Tofacitinib is effective and safe for treating alopecia areata.
1 citations
,
March 2004 in “Journal of the American Academy of Dermatology” ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
4-(Ethoxycarbophenyl) retinamide is much less toxic than other retinoids.
10 citations
,
August 2016 in “Dermatology Online Journal” Nilotinib can cause skin issues like red bumps and hair loss.
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.